Uniqure B.V. News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.08.24	Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid (RTTNews)
09.07.24	UniQure Reports Positive Interim Data From Phase I/II Trials Of AMT-130 - Quick Facts (RTTNews)
12.12.23	CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in Peopl... (PR Newswire)
29.11.23	UniQure Says FDA Clears IND Application For AMT-191 Gene Therapy For Fabry Disease (RTTNews)
27.10.23	CSL and uniQure Win 2023 Prix Galien USA Award (PR Newswire)
05.10.23	UniQure Plans Reorganization, To Cut 114 Jobs; Sees $180 Mln Cost Savings (RTTNews)
02.09.23	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
20.06.23	CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B (PR Newswire)
15.05.23	UniQure To Sell Royalty Interest In HEMGENIX For Up To $400 Mln (RTTNews)
23.02.23	CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb) (PR Newswire)
10.12.22	CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Tr... (PR Newswire)
22.11.22	uniQure announces FDA approval of first gene therapy for adults with hemophilia B (GlobeNewswire)
22.11.22	U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B (PR Newswire)
17.11.22	uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022 (GlobeNewswire)
02.11.22	uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
26.10.22	Biotech Stocks Facing FDA Decision In November 2022 (RTTNews)
11.10.22	uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) (GlobeNewswire)
03.10.22	uniQure to Participate in Upcoming Industry Conferences in October (GlobeNewswire)
06.09.22	uniQure to Participate in Upcoming Industry Conferences in September (GlobeNewswire)
08.08.22	uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
23.06.22	uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease (GlobeNewswire)
22.06.22	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
24.05.22	UniQure: FDA Accepts BLA For Etranacogene Dezaparvovec For Priority Review (RTTNews)
24.05.22	uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review (GlobeNewswire)
11.05.22	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03.05.22	TCMD Expects 13-15% Revenue Growth In 2022, AXSM On Watch, QURE Awaits Huntington's Trial Data (RTTNews)
02.05.22	uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire)
02.05.22	uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
28.03.22	European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B (PR Newswire)
21.03.22	uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
04.03.22	Pre-market Movers: SANW, SWBI, SG, FNKO, WAVE… (RTTNews)
25.02.22	uniQure Announces 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
07.02.22	uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease (GlobeNewswire)
04.02.22	Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022 (PR Newswire)
16.12.21	uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease (GlobeNewswire)
15.12.21	CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B (PR Newswire)
09.12.21	uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B (GlobeNewswire)
02.11.21	uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
01.11.21	uniQure to Participate in Upcoming Industry Conferences in November (GlobeNewswire)
25.10.21	uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
21.10.21	uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors (GlobeNewswire)
19.10.21	uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) (GlobeNewswire)
30.09.21	uniQure to Participate in Multiple Upcoming Industry Conferences in October (GlobeNewswire)
07.09.21	uniQure to Participate in Multiple Upcoming Industry Conferences in September (GlobeNewswire)
07.09.21	Pre-market Movers: IRNT, MTL, IFRX, FWP, JAGX, IPHA… (RTTNews)
04.09.21	Match Group, Ceridian HCM and Brown & Brown Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
30.08.21	uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntingto (GlobeNewswire)
26.07.21	uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
02.07.21	uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress (GlobeNewswire)
22.06.21	uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Uniqure B.V.

Aktien Top/Flop

Meistgelesene Nachrichten